Gala Therapeutics said today it won FDA investigational device exemption approval to conduct an early feasibility study of its RheOx system designed to treat individuals with chronic bronchitis. The study will look to enroll up to 15 patients at five sites in the US, the Menlo Park, Calif.-based company said. “Patients with Chronic Bronchitis suffer […]